TCR2
TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR2 was founded by Dr. Patrick Baeuerle and MPM Capital. It has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
TCR2
Industry:
Biotechnology Health Care Life Science Medical Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.tcr2.com
Total Employee:
101+
Status:
Active
Contact:
617.475.8469
Total Funding:
297.3 M USD
Technology used in webpage:
HSTS IPv6 Akamai Hosted Comcast
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Carisma Therapeutics
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.
Cellares
Cellares is a life sciences technology company that develops the Cell Shuttle to automate cell therapy manufacturing.
Cerevel Therapeutics
Cerevel Therapeutics is a biopharmaceutical company.
Certara
Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development.
Disc Medicine
Disc Medicine is a hematology company
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Insitro
Insitro is a drug discovery and development startup that utilizes machine learning and biology to transform drug discovery.
Rani Therapeutics
Rani Therapeutics develops bio-therapeutics technology for the oral delivery of large drug molecules.
Sanofi
Sanofi is engaged in the research, development, manufacturing, and marketing of innovative therapeutic solutions.
Current Advisors List
Board_member
2015-05-01
Board_member
2018-12-01
Board_member
2015-01-01
Board_member
Board_member
2015-10-01
Current Employees Featured
Patrick Baeuerle Founder @ TCR2
Founder
Greg Sieczkiewicz Chief IP Counsel @ TCR2
Chief IP Counsel
2015-01-01
Helen Ho Vice President, Head of Corporate Development @ TCR2
Vice President, Head of Corporate Development
2016-01-01
Rosemary Harrison Chief Business and Strategy Officer @ TCR2
Chief Business and Strategy Officer
2022-01-01
Founder
Stock Details
Investors List
Haitong International Securities Group
Haitong International Securities Group investment in Series B - TCR2
6 Dimensions Capital
6 Dimensions Capital investment in Series B - TCR2
Sirona Capital
Sirona Capital investment in Series B - TCR2
ArrowMark Partners
ArrowMark Partners investment in Series B - TCR2
Alexandria Venture Investments
Alexandria Venture Investments investment in Series B - TCR2
Syno Capital
Syno Capital investment in Series B - TCR2
curative ventures
curative ventures investment in Series B - TCR2
Hillhouse Investment
Hillhouse Investment investment in Series B - TCR2
Cathay Capital
Cathay Capital investment in Series B - TCR2
F2 Ventures
F2 Ventures investment in Series B - TCR2
Official Site Inspections
http://www.tcr2.com Semrush global rank: 13.25 M Semrush visits lastest month: 78
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "TCR2"
TCR2 - Crunchbase Company Profile & Funding
TCR2 is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a …See details»
Adaptimmune and TCR2 Therapeutics Announce Strategic …
Mar 6, 2023 Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors. Download as PDF March 06, 2023 …See details»
TCR2 Therapeutics Company Profile 2024: Valuation, Investors ...
TCR2 Therapeutics General Information Description. TCR2 Therapeutics Inc is a clinical-stage cell therapy company. It is engaged in developing a pipeline of novel T cell therapies for …See details»
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing …
Jul 20, 2021 “TCR 2 is building a fantastic organization. There is a unique combination of talent, technology, passion and opportunity that has me excited to join at this particular moment in …See details»
TCR2 Therapeutics Company Profile - Office Locations ... - Craft
Jun 1, 2023 TCR2 Therapeutics Summary. Company Summary. Overview. TCR , Inc. is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. …See details»
TCR² Therapeutics Announces Partnership with ElevateBio to …
Nov 10, 2020 “After observing meaningful tumor regression in patients at our first, and presumably suboptimal, TC-210 dose, we are pleased to announce a manufacturing …See details»
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 …
Mar 23, 2023 TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumors Following the expected Q2 2023 …See details»
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 …
Mar 23, 2023 TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumorsFollowing the expected Q2 2023 closing …See details»
TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing …
Jul 20, 2021 TCR2 Therapeutics . Tue, Jul 20, 2021, 6:45 AM 6 min read. ... “TCR 2 is building a fantastic organization. There is a unique combination of talent, technology, passion and …See details»
TCR² Therapeutics Announces Expansion of U.S. Manufacturing …
Nov 1, 2021 About TCR 2 Therapeutics. TCR 2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid …See details»
TCR² Highlights Gavo-cel Translational Data and Emerging
Apr 10, 2021 TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological …See details»
TCR² Therapeutics Receives FDA Orphan Drug Designation for
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of...See details»
TCR² Therapeutics Announces Pipeline Priorities for 2023
TCR2 Therapeutics . Thu, Jan 5, 2023, 8:45 AM 6 min read. TCR2 Therapeutics. gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data …See details»
TCR² Therapeutics Establishes Commercial-Scale Cell Therapy
Mar 29, 2021 85,000 square foot state-of-the-art facility being built in Rockville, MarylandAccelerates TCR2’s commercial-scale manufacturing timelines with production...See details»
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022
Mar 23, 2023 TCR² and Adaptimmune announce strategic combination to create a preeminent cell therapy company focused on treating solid tumors; Following the expected Q2 2023 …See details»
TCR² Therapeutics Announces Expansion of U.S. Manufacturing
Nov 1, 2021 TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors.See details»
TCR² Therapeutics Deepens Manufacturing and Immuno …
The Company’s lead TRuC-T cell product candidate, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer …See details»
TCR² Therapeutics to Highlight Off-the-Shelf TRuC-T Cell at
Mar 8, 2022 Following the Company’s presentation at the medical meeting, the AACR poster presentation will be available on the Company’s website at www.tcr2.com. About TCR 2 …See details»
TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day
ET CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of News Today's newsSee details»
TCR² Therapeutics Announces 2022 Strategic Priorities and …
Jan 10, 2022 TCR2 Therapeutics . Mon, Jan 10, 2022, 6:45 AM 6 min read - Safety Review Team (SRT) identified gavo-cel recommended Phase 2 dose (RP2D) at 1x10 8 cells/m 2See details»